Search for: "AstraZeneca AB"
Results 61 - 80
of 92
Sort by Relevance
|
Sort by Date
7 Mar 2012, 5:32 am
Apotex Pty Ltd v AstraZeneca AB [2011] FCA 1520 (14 December 2011) Interlocutory injunctions – prima facie case – balance of convenience – relevance of delay by patentee, complexity of proceedings, and parties’ conduct and obligations In the first Federal Court decision to follow the ruling of the Full Court in Samsung v Apple (see Samsung v Apple – A Closer Look at the Appeal Decision) Justice Rares has granted a preliminary injunction to… [read post]
5 Dec 2011, 9:59 pm
In Ranbaxy (UK) Ltd v AstraZeneca AB, the England and Wales High Court considered the scope of "Swiss" medical use claims. [read post]
21 Aug 2011, 6:49 pm
Specifically, AstraZeneca AB (“Astra”) contends in a recent Request for Reconsideration of Final Agency Action submitted to the PTO that its PTE application for U.S. [read post]
10 Aug 2011, 4:30 am
(FDA Law Blog) Lipitor (Atorvastatin) – The fight for Atorvastatin: further news (The SPC blog) Nexium (Esomeprazole magnesium) – US: Patent infringement complaint filed following a Paragraph IV certification: Astrazeneca AB et al. v. [read post]
7 Aug 2011, 8:36 pm
Astrazeneca AB et al. v. [read post]
19 Jul 2011, 2:49 am
Supreme Court Duncombe & Ors v Secretary of State for Children, Schools and Families [2011] UKSC 36 (15 July 2011) High Court (Patents Court) Ranbaxy (UK) Ltd v Astrazeneca AB [2011] EWHC 1831 (Pat) (15 July 2011) Select Healthcare (UK) Ltd v Cromptons Healthcare Ltd & Anor [2011] EWHC 1830 (Pat) (15 July 2011) Source: www.bailii.org [read post]
16 Jul 2011, 1:42 am
Ranbaxy (UK) Ltd. v AstraZeneca AB [2011] EWHC 1831 (Pat) (15 July 2011) raises an interesting point on the interpretation of claims. [read post]
31 Mar 2011, 7:46 am
-based AstraZeneca plc announced that it will pay the Internal Revenue Service $1.1 billion to settle all transfer pricing issues for 2000-10, according to a March 28 statement released by the company.Astrazeneca also noted that the company settled with the IRS on the related valuation matter of a 2000 restructuring that followed the 1999 merger of Astra AB and Zeneca Group plc.In addition to the IRS settlement, the company said that the U.S. and U.K. [read post]
14 Mar 2011, 9:50 am
Philips 74 14 Mag Instrument 70 15 Merck 69 16 3M Innovative Properties Company 67 17 Cygnus Telecommunications Technology 64 18 Schering 64 19 Millennium 63 20 Eli Lilly And Company 61 21 Promote Innovation (False Marking) 60 22 Melvino Technologies 59 23 Teva Pharmaceuticals 58 24 AstraZeneca AB 54 25 Eon-Net 54 Rank Patent Plaintiff Number of Defendants Non-Practicing Entity 1 Ronald A Katz Technology… [read post]
1 Mar 2011, 7:35 am
" Astrazeneca AB, et. al. v. [read post]
5 Jan 2011, 1:34 am
General AUTM’s 2010 Better World Report highlights (PatentlyBIOtech) Drug R&D advocate named Kenyan ambassador to UN Geneva (IP Watch) US: Patent eligibility and In re Grams (Patent Docs) US: Main Hastings files false marking complaint against Pfizer based on products from its animal health division (Patent Docs) US: IDEXX files patent infringement complaint against Abbott Laboratories based on its sale of Architect HIV Ag/Ab Combo assay (Patent Docs) US: Life Technologies files… [read post]
22 Dec 2010, 3:01 am
Pfizer Health AB & Anor v Schwarz Pharma AG & Ors (PatLit) US: Briefing updates – AMP v. [read post]
12 Oct 2010, 8:56 pm
Apotex asks Supreme Court to review generic Cozaar/Hyzaar 180-day exclusivity decision (FDA Law Blog) Faslodex (Fulvestrant) – US: AstraZeneca seeks review of BPAI decision concerning patent covering ‘Use of Fulvestrant in treatment of resistant breast cancer’ (Patent Docs) Gemzar (Gemcitabine) – US: Eli Lilly files patent infringement complaint against Dr Reddy’s following Para IV certification (Patent Docs) Lipitor (Atorvastatin) – US: Generic LIPITOR… [read post]
13 Jul 2010, 2:31 am
321/05 AstraZeneca AB v Commission which has been conveniently summarised by Linklaters and Gibson Dunn. [read post]
7 Apr 2010, 4:30 am
Sandoz Pharmaceuticals GmbH et al (EPLAW) Prilosec (Omeprazole) – US: AstraZeneca ordered to pay attorney’s fees for ‘baseless’ suit to protect Prilosec OTC: AstraZeneca AB et al. v. [read post]
1 Apr 2010, 6:22 am
" AstraZeneca AB et al. v. [read post]
10 Mar 2010, 5:22 am
(Patentcircle) (GenericsWeb) Glazide (Gliclazidium) – Poland: Supreme Administrative Court: Glazide is distinctive (Class 46) Januvia (Sitagliptin) - EU: Partial translation of German Sitagliptin referral to the ECJ (The SPC Blog) Nexium IV (Esomeprazole) – US: Infringement of patent following a Paragraph IV certification: AstraZeneca AB et al. v. [read post]
10 Mar 2010, 5:22 am
(Patentcircle) (GenericsWeb) Glazide (Gliclazidium) – Poland: Supreme Administrative Court: Glazide is distinctive (Class 46) Januvia (Sitagliptin) - EU: Partial translation of German Sitagliptin referral to the ECJ (The SPC Blog) Nexium IV (Esomeprazole) – US: Infringement of patent following a Paragraph IV certification: AstraZeneca AB et al. v. [read post]
17 Feb 2010, 8:00 am
Aquatron Inc. and Aqua Group LLC (patent infringement) 1/7: AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited and AstraZeneca AB v. [read post]
6 Oct 2009, 4:00 am
AstraZeneca was formed through a 1999 merger between Britain's Zeneca Group PLC and Sweden's Astra AB, the parent of Astra USA.Corporate boards face mounting pressure to crack down on executives who breach their fiduciary duty, said Thomas C. [read post]
